Sign in Create account

Cipla Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: CIPLA BSE: 500087
₹1346.00
▼ -33.30 (-2.41%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
73/100
Strong
Valuation
29/100
Expensive
Momentum
62/100
Neutral

QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.

Source: Wikipedia

Key Metrics

Market Capitalization
₹108,736 Cr
PE (TTM)
35.4
Industry median 36.1 (152 companies)
Price to Book
3.1
PEG (TTM)
-0.8
Institutions holding %
54.84%
FII + DII, latest filed period
Piotroski Score
2
Relative return vs Nifty50, qtr %
-1.7
Relative return vs Sector, qtr %
-7.6
Free Cash Flow
₹2,341 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-33.85%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-43.12%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-2.95%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-33.84%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
0.62%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
3.44
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.01
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
212.81
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
16.98%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
22.83%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
21.38%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
9.09%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
14.88%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
11.19%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 2)
  • Yes Debt to equity is below 0.5 (0.01)
  • No Return on equity is 15% or more (11.2%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.4%
Low 1346.0000 · High 1384.0000
1W return
-2.7%
Low 1346.0000 · High 1421.0000
1M return
-4.5%
Low 1344.3000 · High 1425.7000
52W return
-11.0%
Low 1165.7000 · High 1673.0000
Lifetime High ₹4984.4000 (Oct. 13, 1999)
Lifetime Low ₹160.1000 (Oct. 24, 2008)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
1372.5
10D
1378.3
20D
1386.2
50D
1401.4
100D
1402.2
200D
1381.5

Delivery and volume

Day avg. delivery
52.4%
Week avg. delivery
52.1%
Month avg. delivery
54.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1358.67
Pivot
First resistance1371.33
Second resistance1396.67
Third resistance1409.33
First support1333.33
Second support1320.67
Third support1295.33
Day RSI35.2
Day MFI54.3
Day MACD-11.17
Day MACD signal-11.53

Beta

1M0.52
3M0.48
1Y0.58
3Y0.53

Price change analysis

↓ -4.5%
Over 1 Month
LowHigh
1344.301425.70
↓ -7.6%
Over 3 Months
LowHigh
1344.301491.20
↑ 12.6%
Over 6 Months
LowHigh
1165.701491.20
↓ -11.0%
Over 1 Year
LowHigh
1165.701673.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 35.4 (own history: 22.3–38.5)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹5,078 Cr
Net profit (June 30, 2026)
₹862 Cr
Basic EPS (June 30, 2026)
₹10.6700

Ranks #5 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter29.21%
  • Mutual funds20.56%
  • FII/FPI20.21%
  • Other DII14.07%
  • Public15.95%

Largest holders

NameCategoryShares %Shares
Yusuf Khwaja HamiedPromoter18.6900%150521183
LICI ULIP-GROWTH FUNDPublic9.7500%78556781
SOPHIE AHMEDPromoter5.7100%45982000
HDFC TRUSTEE COMPANY LIMITED-HDFC FLEXI CAP FUNDPublic4.4800%36089803
M K HAMIEDPromoter3.4600%27844320

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 29.21% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 22.56% to 20.21% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 18.66% to 20.56% in Jun 2026 qtr

95 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 393 insider trades, 37 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
1 Oct 2025 Anusha Jain jointly with Dinesh Jain Immediate relative Sell 0 ₹0
1 Oct 2025 Renu Jain jointly with Dinesh Jain Immediate relative Buy 0 ₹0
22 Aug 2024 Anusha Jain Immediate relative Sell 0 ₹0
14 Aug 2024 Anusha Jain Immediate relative Sell 0 ₹0
18 Oct 2023 Priyanka Mallick Employee / designated person Buy 0 ₹0
18 Oct 2023 Priyanka Mallick Employee / designated person Buy 0 ₹0
18 Oct 2023 Jaideep Mallick Immediate relative Buy 0 ₹0
13 Apr 2023 Vidya Prabhakar Rote jointly with Kiran Rote Other Pledge 0 ₹11.19 L
13 Apr 2023 Vidya Prabhakar Rote jointly with Kiran Rote Other Buy 0 ₹0
13 Apr 2023 Vidya Prabhakar Rote jointly with Kiran Rote Other Pledge Revoke 0 ₹10.76 L

All insider and SAST disclosures →

Deals (Bulk & Block)

All 183 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
16 Oct 2025 GOLDMAN SACHS BANK EUROPESE - ODI Block Buy 91,604 1565.0000 NSE
16 Oct 2025 GOLDMAN SACHS (SINGAPORE) PTE.- ODI Block Sell 91,604 1565.0000 NSE
14 Jul 2025 THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849 Block Buy 156,532 1485.0000 NSE
14 Jul 2025 THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828 Block Sell 156,532 1485.0000 NSE
2 Dec 2024 UBS PRINCIPAL CAPITAL ASIA LIMITED Block Buy 139,082 1518.7500 NSE
2 Dec 2024 TATA AIA LIFE INSURANCE COMPANY LIMITED Block Buy 322,676 1518.7500 NSE
2 Dec 2024 SOCIETE GENERALE Block Buy 216,967 1518.7500 NSE
2 Dec 2024 SBI LIFE INSURANCE COMPANY LIMITED Block Buy 611,969 1518.7500 NSE
2 Dec 2024 SAMINA HAMIED Block Sell 8,954,750 1518.7500 NSE
2 Dec 2024 RUMANA HAMIED Block Sell 4,943,250 1518.7500 NSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹13.00 per share
Dividend yield 0.97%
Ex-dateSubjectPer share (₹)Record date
5 Jun 2026 Dividend - Rs 13 Per Share 13.0000 5 Jun 2026
27 Jun 2025 Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share 13.0000 27 Jun 2025
2 Aug 2024 Dividend - Rs 13 Per Share 13.0000 2 Aug 2024
21 Jul 2023 Dividend - Rs 8.50 Per Share 8.5000 21 Jul 2023
8 Aug 2022 Dividend - Rs 5 Per Share 5.0000 10 Aug 2022
9 Aug 2021 Annual General Meeting/Dividend - Rs 5 Per Share 5.0000 —
19 Mar 2020 Interim Dividend - Rs 3 Per Share Special Dividend - Re 1 Per Share 3.0000 20 Mar 2020
31 Jul 2019 Annual General Meeting/Dividend - Rs 3 Per Share 3.0000 —
13 Aug 2018 Annual General Meeting/Dividend- Rs 3 Per Share 3.0000 —
26 Jul 2017 Annual General Meeting/Dividend - Rs 2/- Per Share 2.0000 —

Corporate Actions

Full history (25 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
24 Apr 2006BONUSBonus 3:2
11 Aug 2020OTHER Annual General Meeting
10 Aug 2009AGMAgm/Div-Rs.2/- Per Share
8 Aug 2007AGMAgm/Div-Rs.2/- Per Sh
18 Aug 2006AGMAgm/Div-Rs.2/- Per Sh
19 Aug 2005AGMAgm/Div-Rs.3.5/- Per Sh Purpose Revised

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
23 Jul 2026 Financial Results Yes
13 May 2026 Financial Results/Dividend/Other business matters Yes
23 Jan 2026 Financial Results Yes
30 Oct 2025 Financial Results Yes
25 Jul 2025 Financial Results Yes

Corporate Announcements

All 1585 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Board Meeting Cipla Ltd - 500087 - Board Meeting Intimation for The Quarter And Half Year Ended 30Th September, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
24 Sep 2026 ESOP/ESOS/ESPS Cipla Limited has informed the Exchange regarding Allotment of 12168 Shares.
22 Sep 2026 Change in Management Cipla Limited has informed the Exchange about change in Senior Management Personnel.
18 Sep 2026 Company Update Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
18 Sep 2026 General Updates Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
3 Sep 2026 Press Release Cipla Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US".
3 Sep 2026 General Updates Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company.
2 Sep 2026 Copy of Newspaper Publication Cipla Limited has informed the Exchange about Newspaper Publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares
31 Aug 2026 Press Release Cipla Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)".
28 Aug 2026 General Updates Cipla Limited has informed the Exchange about Update on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.01)
  • Comfortable interest coverage (212.8x)

Weaknesses

  • Declining profit YoY (-33.8%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (35.4) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.

Part of: NIFTY 100, NIFTY 100, NIFTY 200, NIFTY 200, NIFTY 50, NIFTY 50, NIFTY 500, NIFTY 500, NIFTY PHARMA, NIFTY PHARMA

Frequently asked questions about Cipla Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.